nach oben

Current Diabetes Reports

Erschienen in:

01.09.2020 | Genetics (AP Morris, Section Editor)

New Insights into the Genetics of Latent Autoimmune Diabetes in Adults

verfasst von: Mette K. Andersen

Erschienen in: Current Diabetes Reports | Ausgabe 9/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Diabetes is a spectrum of clinical manifestations, including latent autoimmune diabetes in adults (LADA). However, it has been questioned whether LADA exists or simply is a group of misclassified type 1 diabetes (T1D) and type 2 diabetes (T2D) patients. This review will provide an updated overview of the genetics of LADA, highlight what genetics tell us about LADA as a diabetes subtype, and point to future directions in the study of LADA.

Recent Findings

Recent studies have verified the genetic overlap between LADA and both T1D and T2D and have contributed identification of a novel LADA-specific locus, namely, PFKFB3, and subtype-specific signatures in the HLA region. Genetic risk scores comprising T1D-risk variants have been shown to be a promising tool for discriminating diabetes subtypes and identifying patients rapidly progressing to insulin dependence.

Summary

Genetic data support the existence of LADA, but further studies are needed to fully determine the place of LADA in the diabetes spectrum.

Zimmet PZ, Magliano DJ, Herman WH, Shaw JE. Diabetes: a 21st century challenge. Lancet Diabetes Endocrinol. 2014;2:56–64.PubMed

Bommer C, Sagalova V, Heesemann E, Manne-Goehler J, Atun R, Bärnighausen T, et al. Global economic burden of diabetes in adults: projections from 2015 to 2030. Diabetes Care. 2018;41:963–70.PubMed

https://www.who.int/news-room/fact-sheets/detail/diabetes; accessed June 20^th 2020.

WHO, Classification of diabetes mellitus 2019. Available at: https://www.who.int/publications-detail/classification-of-diabetes-mellitus.

Tuomi T, Carlsson A, Li H, Isomaa B, Miettinen A, Nilsson A, et al. Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes. 1999;48:150–7.PubMed

Zinman B, Kahn SE, Haffner SM, O’Neill MC, Heise MA, Freed MI, et al. Phenotypic characteristics of GAD antibody-positive recently diagnosed patients with type 2 diabetes in North America and Europe. Diabetes. 2004;53:3193–200.PubMed

Hawa MI, Thivolet C, Mauricio D, Alemanno I, Cipponeri E, Collier D, et al. Metabolic syndrome and autoimmune diabetes: action LADA 3. Diabetes Care. 2009;32:160–4.PubMedPubMedCentral

Andersen MK, Lundgren V, Turunen JA, Forsblom C, Isomaa B, Groop PH, et al. Latent autoimmune diabetes in adults differs genetically from classical type 1 diabetes diagnosed after the age of 35 years. Diabetes Care. 2010;33:2062–4.PubMedPubMedCentral

Zhou Z, Xiang Y, Ji L, Jia W, Ning G, Huang G, et al. Frequency, immunogenetics, and clinical characteristics of latent autoimmune diabetes in China (LADA China study): a nationwide, multicenter, clinic-based cross-sectional study. Diabetes. 2013;62:543–50.PubMedPubMedCentral

10.

Tuomi T, Santoro N, Caprio S, Cai M, Weng J, Groop L. The many faces of diabetes: a disease with increasing heterogeneity. Lancet. 2014;383:1084–94.PubMed

11.

Hjort R, Ahlqvist E, Carlsson PO, Grill V, Groop L, Martinell M, et al. Overweight, obesity and the risk of LADA: results from a Swedish case–control study and the Norwegian HUNT Study. Diabetologia. 2018;61:1333–43.PubMedPubMedCentral

12.

Hjort R, Alfredsson L, Andersson T, Carlsson P-O, Grill V, Groop L, et al. Family history of type 1 and type 2 diabetes and risk of latent autoimmune diabetes in adults (LADA). Diabetes Metab. 2017;43:536–42.PubMed

13.

Jörns A, Arndt T, Zu Vilsendorf AM, Klempnauer J, Wedekind D, Hedrich HJ, et al. Islet infiltration, cytokine expression and beta cell death in the NOD mouse, BB rat, Komeda rat, LEW.1AR1-iddm rat and humans with type 1 diabetes. Diabetologia. 2014;57:512–21.PubMed

14.

Campbell-Thompson M, Fu A, Kaddis JS, Wasserfall C, Schatz DA, Pugliese A, et al. Insulitis and β-cell mass in the natural history of type 1 diabetes. Diabetes. 2016;65:719–31.PubMed

15.

Jörns A, Wedekind D, Jähne J, Lenzen S. Pancreas pathology of latent autoimmune diabetes in adults (LADA) in patients and in a LADA rat model compared with type 1 diabetes. Diabetes. 2020;69:624–33.PubMed

16.

Wod M, Thomsen RW, Pedersen L, Yderstraede KB, Beck-Nielsen H, Højlund K. Lower mortality and cardiovascular event rates in patients with latent autoimmune diabetes in adults (LADA) as compared with type 2 diabetes and insulin deficient diabetes: a cohort study of 4368 patients. Diabetes Res Clin Pract. 2018;139:107–13.PubMed

17.

Maddaloni E, Coleman RL, Pozzilli P, Holman RR. Long-term risk of cardiovascular disease in individuals with latent autoimmune diabetes in adults (UKPDS 85). Diabetes Obes Metab. 2019;21:2115–22.PubMed

18.

Maddaloni E, Coleman RL, Agbaje O, Buzzetti R, Holman RR. Time-varying risk of microvascular complications in latent autoimmune diabetes of adulthood compared with type 2 diabetes in adults: a post-hoc analysis of the UK Prospective Diabetes Study 30-year follow-up data (UKPDS 86). Lancet Diabetes Endocrinol. 2020;8:206–15.PubMed

19.

Ahlqvist E, Storm P, Käräjämäki A, Martinell M, Dorkhan M, Carlsson A, et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol. 2018;6:361–9.PubMed

20.

Castelblanco E, Hernandez M, Castelblanco A, Gratacos M, Esquerda A, Mollo A, et al. Low-grade inflammatory marker profile may help to differentiate patients with LADA, classic adult-onset type 1 diabetes, and type 2 diabetes. Diabetes Care. 2018;41:862–8.PubMed

21.

Tong Y, Yang L, Shao F, Yan X, Li X, Huang G, et al. Distinct secretion pattern of serum proinsulin in different types of diabetes. Ann Transl Med. 2020;8:452.PubMedPubMedCentral

22.

Sørgjerd EP. Type 1 diabetes-related autoantibodies in different forms of diabetes. Curr Diabetes Rev. 2019;15:199–204.PubMed

23.

Singal DP, Blajchman MA. Histocompatibility (HL-A) antigens, lymphocytotoxic antibodies and tissue antibodies in patients with diabetes mellitus. Diabetes. 1973;22:429–32.PubMed

24.

Nerup J, Platz P, Andersen OO, Christy M, Lyngsoe J, Poulsen JE, et al. HL-A antigens and diabetes mellitus. Lancet. 1974;2:864–6.PubMed

25.

Barrett JC, Clayton DG, Concannon P, Akolkar B, Cooper JD, Erlich HA, et al. Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat Genet. 2009;41:703–7.PubMedPubMedCentral

26.

Bradfield JP, Qu HQ, Wang K, Zhang H, Sleiman PM, Kim CE, et al. A genome-wide meta-analysis of six type 1 diabetes cohorts identifies multiple associated loci. PLoS Genet. 2011;7:e1002293.PubMedPubMedCentral

27.

Onengut-Gumuscu S, Chen W-M, Burren O, Cooper NJ, Quinlan AR, Mychaleckyj JC, et al. Fine mapping of type 1 diabetes susceptibility loci and evidence for colocalization of causal variants with lymphoid gene enhancers. Nat Genet. 2015;47:381–6.PubMedPubMedCentral

28.

Mahajan A, Taliun D, Thurner M, Robertson NR, Torres JM, Rayner NW, et al. Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps. Nat Genet. 2018;50:1505–13.PubMedPubMedCentral

29.

Eftychi C, Howson JM, Barratt BJ, Vella A, Payne F, Smyth DJ, et al. Analysis of the type 2 diabetes-associated single nucleotide polymorphisms in the genes IRS1, KCNJ11, and PPARG2 in type 1 diabetes. Diabetes. 2004;53:870–3.PubMed

30.

Raj SM, Howson JM, Walker NM, Cooper JD, Smyth DJ, Field SF, et al. No association of multiple type 2 diabetes loci with type 1 diabetes. Diabetologia. 2009;52:2109–16.PubMedPubMedCentral

31.

Mahajan A, Go MJ, Zhang W, Below JE, Gaulton KJ, Ferreira T, et al. Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. Nat Genet. 2014;46:234–44.PubMed

32.

• Aylward A, Chiou J, Okino M-L, Kadakia N, Gaulton KJ. Shared genetic risk contributes to type 1 and type 2 diabetes etiology. Hum Mol Genet. 2018. https://doi.org/10.1093/hmg/ddy314 Online ahead of print. Important study comprehensively examining the genetic overlap between type 1 and type 2 diabetes.

33.

McKeigue PM, Spiliopoulou A, McGurnaghan S, Colombo M, Blackbourn L, McDonald TJ, et al. Persistent C-peptide secretion in type 1 diabetes and its relationship to the genetic architecture of diabetes. BMC Med. 2019;17:165.PubMedPubMedCentral

34.

Dooley J, Tian L, Schonefeldt S, Delghingaro-Augusto V, Garcia-Perez JE, Pasciuto E, et al. Genetic predisposition for beta cell fragility underlies type 1 and type 2 diabetes. Nat Genet. 2016;48:519–27.PubMedPubMedCentral

35.

Liston A, Todd JA, Lagou V. Beta-cell fragility as a common underlying risk factor in type 1 and type 2 diabetes. Trends Mol Med. 2017;23:181–94.PubMed

36.

Battaglia M, Ahmed S, Anderson MS, Atkinson MA, Becker D, Bingley PJ, et al. Introducing the endotype concept to address the challenge of disease heterogeneity in type 1 diabetes. Diabetes Care. 2020;43:5–12.PubMed

37.

Howson JM, Walker NM, Clayton D, Todd JA, Consortium T 1 DG. Confirmation of HLA class II independent type 1 diabetes associations in the major histocompatibility complex including HLA-B and HLA-A. Diabetes Obes Metab 2009:11 Suppl 1:31–45.

38.

Sabbah E, Savola K, Ebeling T, Kulmala P, Vahasalo P, Ilonen J, et al. Genetic, autoimmune, and clinical characteristics of childhood- and adult-onset type 1 diabetes. Diabetes Care. 2000;23:1326–32.PubMed

39.

Desai M, Zeggini E, Horton VA, Owen KR, Hattersley AT, Levy JC, et al. An association analysis of the HLA gene region in latent autoimmune diabetes in adults. Diabetologia. 2007;50:68–73.PubMed

40.

Cervin C, Lyssenko V, Bakhtadze E, Lindholm E, Nilsson P, Tuomi T, et al. Genetic similarities between latent autoimmune diabetes in adults, type 1 diabetes, and type 2 diabetes. Diabetes. 2008;57:1433–7.PubMed

41.

Luo S, Lin J, Xie Z, Xiang Y, Zheng P, Huang G, et al. HLA genetic discrepancy between latent autoimmune diabetes in adults and type 1 diabetes: LADA China study no. 6. J Clin Endocrinol Metab. 2016;101:1693–700.PubMed

42.

• Mishra R, Chesi A, Cousminer DL, Hawa MI, Bradfield JP, Hodge KM, et al. Relative contribution of type 1 and type 2 diabetes loci to the genetic etiology of adult-onset, non-insulin-requiring autoimmune diabetes 2017:15:88. Study including interesting analysis of type 1 diabetes and type 2 diabetes genetic risk scores in LADA.

43.

•• Cousminer DL, Ahlqvist E, Mishra R, Andersen MK, Chesi A, Hawa MI, et al. First genome-wide association study of latent autoimmune diabetes in adults reveals novel insights linking immune and metabolic diabetes. Diabetes Care 2018:11:2396–403. First genome-wide association study of LADA contributing with important findings, including the LADA-specific association in the PFKFB3 locus.

44.

Pettersen E, Skorpen F, Kvaloy K, Midthjell K, Grill V. Genetic heterogeneity in latent autoimmune diabetes is linked to various degrees of autoimmune activity: results from the Nord-Trondelag Health Study. Diabetes. 2010;59:302–10.PubMed

45.

•• Mishra R, Åkerlund M, Cousminer DL, Ahlqvist E, Bradfield JP, Chesi A, et al. Genetic discrimination between LADA and childhood-onset type 1 diabetes within the MHC. Diabetes Care 2020:43:418–25. Comprehensive analyses of the impact of variants in the HLA region in LADA and type 1 diabetes. The study identifies important genetic difference between LADA and type 1 diabetes.

46.

Valdes AM, Erlich HA, Noble JA. Human leukocyte antigen class I B and C loci contribute to type 1 diabetes (T1D) susceptibility and age at T1D onset. Hum Immunol. 2005;66:301–13.PubMedPubMedCentral

47.

Nejentsev S, Howson JM, Walker NM, Szeszko J, Field SF, Stevens HE, et al. Localization of type 1 diabetes susceptibility to the MHC class I genes HLA-B and HLA-A. Nature. 2007;450:887–92.PubMedPubMedCentral

48.

Schloss J, Ali R, Racine JJ, Chapman HD, Serreze DV, DiLorenzo TP. HLA-B*39:06 efficiently mediates type 1 diabetes in a mouse model incorporating reduced thymic insulin expression. J Immunol. 2018;200:3353–63.PubMed

49.

Pugliese A. Pathogenesis of type 1 diabetes: genetics. Int diabetes Monit. 2010;22:101–11.

50.

Nepom GT, Kwok WW. Molecular basis for HLA-DQ associations with IDDM. Diabetes. 1998;47:1177–84.PubMed

51.

Lee KH, Wucherpfennig KW, Wiley DC. Structure of a human insulin peptide-HLA-DQ8 complex and susceptibility to type 1 diabetes. Nat Immunol. 2001;2:501–7.PubMed

52.

Peng H, Zhou M, Xu WD, Xu K, Zhai Y, Li R, et al. Association of PTPN22 C1858T polymorphism and type 1 diabetes: a meta-analysis. Immunol Investig. 2012;41:484–96.

53.

Petrone A, Suraci C, Capizzi M, Giaccari A, Bosi E, Tiberti C, et al. The protein tyrosine phosphatase nonreceptor 22 (PTPN22) is associated with high GAD antibody titer in latent autoimmune diabetes in adults: non insulin requiring autoimmune diabetes (NIRAD) study 3. Diabetes Care. 2008;31:534–8.PubMed

54.

Heneberg P, Kocková L, Čecháková M, Daňková P, Černá M. Autoimmunity-associated PTPN22 polymorphisms in latent autoimmune diabetes of the adult differ from those of type 1 diabetes patients. Int Arch Allergy Immunol. 2018;177:57–68.PubMed

55.

Liu F, Liu J, Shan ZT, Li Q, Wang C, Ping PX, et al. The -1123G>C variant of PTPN22 gene promoter is associated with latent autoimmune diabetes in adult Chinese Hans. Cell Biochem Biophys. 2012;62:273–9.PubMed

56.

Ramu D, Perumal V, Paul SFD. Association of common type 1 and type 2 diabetes gene variants with latent autoimmune diabetes in adults: a meta-analysis. J Diabetes. 2019;11:484–96.PubMed

57.

Liu YC, Gu H. Cbl and Cbl-b in T-cell regulation. Trends Immunol. 2002;23:140–3.PubMed

58.

Hill RJ, Zozulya S, Lu YL, Ward K, Gishizky M, Jallal B. The lymphoid protein tyrosine phosphatase Lyp interacts with the adaptor molecule Grb2 and functions as a negative regulator of T-cell activation. Exp Hematol. 2002;30:237–44.PubMed

59.

Wu J, Katrekar A, Honigberg LA, Smith AM, Conn MT, Tang J, et al. Identification of substrates of human protein-tyrosine phosphatase PTPN22. J Biol Chem. 2006;281:11002–10.PubMed

60.

Rieck M, Arechiga A, Onengut-Gumuscu S, Greenbaum C, Concannon P, Buckner JH. Genetic variation in PTPN22 corresponds to altered function of T and B lymphocytes. J Immunol. 2007;179:4704–10.PubMed

61.

Sharp RC, Abdulrahim M, Naser ES, Naser SA. Genetic variations of PTPN2 and PTPN22: role in the pathogenesis of type 1 diabetes and Crohn’s disease. Front Cell Infect Microbiol. 2015;5:95.PubMedPubMedCentral

62.

Todd JA, Walker NM, Cooper JD, Smyth DJ, Downes K, Plagnol V, et al. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet. 2007;39:857–64.PubMedPubMedCentral

63.

Bennett ST, Lucassen AM, Gough SC, Powell EE, Undlien DE, Pritchard LE, et al. Susceptibility to human type 1 diabetes at IDDM2 is determined by tandem repeat variation at the insulin gene minisatellite locus. Nat Genet. 1995;9:284–92.PubMed

64.

Desai M, Zeggini E, Horton VA, Owen KR, Hattersley AT, Levy JC, et al. The variable number of tandem repeats upstream of the insulin gene is a susceptibility locus for latent autoimmune diabetes in adults. Diabetes. 2006;55:1890–4.PubMed

65.

•• Sharp SA, Rich SS, Wood AR, Jones SE, Beaumont RN, Harrison JW, et al. Development and standardization of an improved type 1 diabetes genetic risk score for use in newborn screening and incident diagnosis. Diabetes Care 2019:42:200–7. Important study demonstrating the utility of a type 1 diabetes genetic risk score in discriminating type 1 diabetes from population controls as well as patients with type 2 diabetes.

66.

Pugliese A, Zeller M, Fernandez A Jr, Zalcberg LJ, Bartlett RJ, Ricordi C, et al. The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes. Nat Genet. 1997;15:293–7.PubMed

67.

Vafiadis P, Bennett ST, Todd JA, Nadeau J, Grabs R, Goodyer CG, et al. Insulin expression in human thymus is modulated by INS VNTR alleles at the IDDM2 locus. Nat Genet. 1997;15:289–92.PubMed

68.

Pugliese A. The insulin gene in type 1 diabetes. IUBMB Life. 2005;57:463–8.PubMed

69.

Sparks AE, Chen C, Breslin MB, Lan MS. Functional domains of autoimmune regulator (AIRE) modulate INS-VNTR transcription in human thymic epithelial cells. J Biol Chem. 2016;291:11313–22.PubMedPubMedCentral

70.

Dale BL, Madhur MS. Linking inflammation and hypertension via LNK/SH2B3. Curr Opin Nephrol Hypertens. 2016;25:87–93.PubMedPubMedCentral

71.

Auburger G, Gispert S, Lahut S, Omür O, Damrath E, Heck M, et al. 12q24 locus association with type 1 diabetes: SH2B3 or ATXN2 ? World J Diabetes. 2014;5:316–27.PubMedPubMedCentral

72.

Maslah N, Cassinat B, Verger E, Kiladjian JJ, Velazquez L. The role of LNK/SH2B3 genetic alterations in myeloproliferative neoplasms and other hematological disorders. Leukemia. 2017;31:1661–70.PubMed

73.

Devallire J, Charreau B. The adaptor Lnk (SH2B3): an emerging regulator in vascular cells and a link between immune and inflammatory signaling. Biochem Pharmacol. 2011;82:1391–402.

74.

Perez-Garcia A, Ambesi-Impiombato A, Hadler M, Rigo I, LeDuc CA, Kelly K, et al. Genetic loss of SH2B3 in acute lymphoblastic leukemia. Blood. 2013;122:2425–32.PubMedPubMedCentral

75.

Mori T, Suzuki-Yamazaki N, Takaki S. Lnk/Sh2b3 regulates adipose inflammation and glucose tolerance through group 1 ILCs. Cell Rep. 2018;24:1830–41.PubMed

76.

Grant SF, Thorleifsson G, Reynisdottir I, Benediktsson R, Manolescu A, Sainz J, et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet. 2006;38:320–3.PubMed

77.

Helgason A, Pálsson S, Thorleifsson G, Grant SFA, Emilsson V, Gunnarsdottir S, et al. Refining the impact of TCF7L2 gene variants on type 2 diabetes and adaptive evolution. Nat Genet. 2007;39:218–25.PubMed

78.

Gaulton KJ, Nammo T, Pasquali L, Simon JM, Giresi PG, Fogarty MP, et al. A map of open chromatin in human pancreatic islets. Nat Genet. 2010;42:255–9.PubMedPubMedCentral

79.

Lukacs K, Hosszufalusi N, Dinya E, Bakacs M, Madacsy L, Panczel P. The type 2 diabetes-associated variant in TCF7L2 is associated with latent autoimmune diabetes in adult Europeans and the gene effect is modified by obesity: a meta-analysis and an individual study. Diabetologia. 2012;55:689–93.PubMed

80.

Andersen MK, Sterner M, Forsén T, Käräjämäki A, Rolandsson O, Forsblom C, et al. Type 2 diabetes susceptibility gene variants predispose to adult-onset autoimmune diabetes. Diabetologia. 2014;57:1859–68.PubMed

81.

Zampetti S, Spoletini M, Petrone A, Capizzi M, Arpi ML, Tiberti C, et al. Association of TCF7L2 gene variants with low GAD autoantibody titre in LADA subjects (NIRAD Study 5). Diabet Med. 2010;27:701–4.PubMed

82.

Qu HQ, Polychronakos C. The TCF7L2 locus and type 1 diabetes. BMC Med Genet. 2007;8:51.PubMedPubMedCentral

83.

Field SF, Howson JM, Smyth DJ, Walker NM, Dunger DB, Todd JA. Analysis of the type 2 diabetes gene, TCF7L2, in 13,795 type 1 diabetes cases and control subjects. Diabetologia. 2007;50:212–3.PubMed

84.

Winkler C, Raab J, Grallert H, Ziegler AG. Lack of association of type 2 diabetes susceptibility genotypes and body weight on the development of islet autoimmunity and type 1 diabetes. PLoS One. 2012;7:e35410.PubMedPubMedCentral

85.

Yu J, Steck AK, Babu S, Yu L, Miao D, McFann K, et al. Single nucleotide transcription factor 7-like 2 (TCF7L2) gene polymorphisms in antiislet autoantibody-negative patients at onset of diabetes. J Clin Endocrinol Metab. 2009;94:504–10.PubMed

86.

Redondo MJ, Geyer S, Steck AK, Sosenko J, Anderson M, Antinozzi P, et al. TCF7L2 genetic variants contribute to phenotypic heterogeneity of type 1 diabetes. Diabetes Care. 2018;41:311–7.PubMed

87.

Yi F, Brubaker PL, Jin T. TCF-4 mediates cell type-specific regulation of proglucagon gene expression by β-catenin and glycogen synthase kinase-3β. J Biol Chem. 2005;280:1457–64.PubMed

88.

Liu Z, Habener JF. Glucagon-like peptide-1 activation of TCF7L2-dependent Wnt signaling enhances pancreatic beta cell proliferation. J Biol Chem. 2008;283:8723–35.PubMedPubMedCentral

89.

Florez JC, Jablonski KA, Bayley N, Pollin TI, De Bakker PIW, Shuldiner AR, et al. TCF7L2 polymorphisms and progression to diabetes in the diabetes prevention program. N Engl J Med. 2006;355:241–50.PubMedPubMedCentral

90.

Saxena R, Gianniny L, Burtt NP, Lyssenko V, Giuducci C, Sjogren M, et al. Common single nucleotide polymorphisms in TCF7L2 are reproducibly associated with type 2 diabetes and reduce the insulin response to glucose in nondiabetic individuals. Diabetes. 2006;55:2890–5.PubMed

91.

Lyssenko V, Lupi R, Marchetti P, Del Guerra S, Orho-Melander M, Almgren P, et al. Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J Clin Invest. 2007;117:2155–63.PubMedPubMedCentral

92.

Chen X, Ayala I, Shannon C, Fourcaudot M, Acharya NK, Jenkinson CP, et al. The diabetes gene and wnt pathway effector TCF7L2 regulates adipocyte development and function. Diabetes. 2018;67:554–68.PubMedPubMedCentral

93.

Kaminska D, Kuulasmaa T, Venesmaa S, Käkelä P, Vaittinen M, Pulkkinen L, et al. Adipose tissue TCF7L2 splicing is regulated by weight loss and associates with glucose and fatty acid metabolism. Diabetes. 2012;61:2807–13.PubMedPubMedCentral

94.

Kirkpatrick CL, Marchetti P, Purrello F, Piro S, Bugliani M, Bosco D, et al. Type 2 diabetes susceptibility gene expression in normal or diabetic sorted human alpha and beta cells: correlations with age or BMI of islet donors. PLoS One. 2010;5:e11053.PubMedPubMedCentral

95.

Duran J, Obach M, Navarro-Sabate A, Manzano A, Gómez M, Rosa JL, et al. Pfkfb3 is transcriptionally upregulated in diabetic mouse liver through proliferative signals. FEBS J. 2009;276:4555–68.PubMed

96.

Atsumi T, Nishio T, Niwa H, Takeuchi J, Bando H, Shimizu C, et al. Expression of inducible 6-phosphofructo-2-kinase/fructose-2,6- bisphosphatase/PFKFB3 isoforms in adipocytes and their potential role in glycolytic regulation. Diabetes. 2005;54:3349–57.PubMed

97.

Huo Y, Guo X, Li H, Wang H, Zhang W, Wang Y, et al. Disruption of inducible 6-phosphofructo-2-kinase ameliorates diet-induced adiposity but exacerbates systemic insulin resistance and adipose tissue inflammatory response. J Biol Chem. 2010;285:3713–21.PubMed

98.

Huo Y, Guo X, Li H, Xu H, Halim V, Zhang W, et al. Targeted overexpression of inducible 6-phosphofructo-2-kinase in adipose tissue increases fat deposition but protects against diet-induced insulin resistance and inflammatory responses. J Biol Chem. 2012;287:21492–500.PubMedCentralPubMed

99.

Montemurro C, Nomoto H, Pei L, Parekh VS, Vongbunyong KE, Vadrevu S, et al. IAPP toxicity activates HIF1α/PFKFB3 signaling delaying β-cell loss at the expense of β-cell function. Nat Commun. 2019;10:2679.PubMedPubMedCentral

100.

Nomoto H, Pei L, Montemurro C, Rosenberger M, Furterer A, Coppola G, et al. Activation of the HIF1α/PFKFB3 stress response pathway in beta cells in type 1 diabetes. Diabetologia. 2020;63:149–61.PubMed

101.

Udler MS, McCarthy MI, Florez JC, Mahajan A. Genetic risk scores for diabetes diagnosis and precision medicine. Endocr Rev. 2019;40:1500–20.PubMedPubMedCentral

102.

Khera AV, Chaffin M, Aragam KG, Haas ME, Roselli C, Choi SH, et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet. 2018;50:1219–24.PubMedPubMedCentral

103.

The risk-screening converter. Available from: https://www.lmsalpha.co.uk/rsc. Accessed June 20^th 2020.

104.

Wald NJ, Old R. The illusion of polygenic disease risk prediction. Genetics in Medicine. 2019;21:1705–7.PubMed

105.

Oram RA, Patel K, Hill A, Shields B, McDonald TJ, Jones A, et al. A type 1 diabetes genetic risk score can aid discrimination between type 1 and type 2 diabetes in young adults. Diabetes Care. 2016;39:337–44.PubMed

106.

•• Grubb AL, McDonald TJ, Rutters F, Donnelly LA, Hattersley AT, Oram RA, et al. A type 1 diabetes genetic risk score can identify patients with GAD65 autoantibody–positive type 2 diabetes who rapidly progress to insulin therapy. Diabetes Care 2019:42:208–14. Important study demonstrating the utility of a type 1 diabetes genetic risk score in discriminating GAD autoantibody positive type 2 diabetes patients rapidly progressing to insulin therapy.

107.

Udler MS, Kim J, von Grotthuss M, Bonàs-Guarch S, Cole JB, Chiou J, et al. Type 2 diabetes genetic loci informed by multi-trait associations point to disease mechanisms and subtypes: a soft clustering analysis. PLoS Med. 2018;15:e1002654.PubMedPubMedCentral

Titel: New Insights into the Genetics of Latent Autoimmune Diabetes in Adults
verfasst von: Mette K. Andersen
Publikationsdatum: 01.09.2020
Verlag: Springer US
Erschienen in: Current Diabetes Reports / Ausgabe 9/2020
Print ISSN: 1534-4827
Elektronische ISSN: 1539-0829
DOI: https://doi.org/10.1007/s11892-020-01330-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2020

Endocrine Mechanisms Connecting Exercise to Brown Adipose Tissue Metabolism: a Human Perspective

Early Onset of Autoimmune Diabetes in Children with Down Syndrome—Two Separate Aetiologies or an Immune System Pre-Programmed for Autoimmunity?

Lipidomic Abnormalities During the Pathogenesis of Type 1 Diabetes: a Quantitative Review

miRNA Regulation of T Cells in Islet Autoimmunity and Type 1 Diabetes

Type 2 Diabetes in Youth: the Role of Early Life Exposures